Publication details

Účinnost dienogestu v terapii klinických symptomů endometriózy rektovaginálního septa

Title in English Efficacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis
Authors

PAPÍKOVÁ Z. HUDEČEK Robert VENTRUBA Pavel SZYPULOVÁ M.

Year of publication 2019
Type Article in Periodical
Magazine / Source ČESKÁ GYNEKOLOGIE-CZECH GYNAECOLOGY
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.prolekare.cz/casopisy/ceska-gynekologie/2019-5-8/ucinnost-dienogestu-v-terapii-klinickych-symptomu-endometriozy-rektovaginalniho-septa-118511
Keywords endometriosis; rectovaginal septum; dyspareunia; pelvic pain; dienogest
Description Objective: The aim of this prospective, unicentric, cohort study was to evaluate the effect of dienogest use in the therapy of symptomatic endometriosis of rectovaginal septum in patients of fertile age. Study design: Prospective, unicentric, cohort study. Setting: Department of Obstetrics and Gynaecology, Brno University Hospital and Masaryk University Medical School. Brno. Material and methods: Prospective analysis of the group of 32 patients in reproductive age who have previously been diagnosed with endometriosis of rectovaginal septum. These patients were treated conservatively with dienogest 2 mg per day during a 24-week period. Through questionnaires and clinical assessment, we have studied the presence of symptoms like dyspareunia, diffuse pelvic pain, Biberoglu-Behrman(B-B) score assessment and subjective pain perception using Visual Analogue Scale (VAS) of pain. Data were collected at the beginning of therapy, after 4, 12 and 24 weeks of dienogest use. Results: Continual use of dienogest during the 24-week period diminishes symptoms of dyspareunia by 62% (p < 0.001), diffuse pelvic pain by 44% (p = 0,001), mean B-B score by 5.31 points and median VAS scale of 20 points (p < 0.001) in patients with a rectovaginal form of endometriosis. Conclusion: We proved that continuous therapy of 2 mg of dienogest daily in the 24-week period is effective in reducing clinical symptoms like dyspareunia and diffuse pelvic pain in patients with endometriosis of rectovaginal septum during their reproductive age.

You are running an old browser version. We recommend updating your browser to its latest version.

More info